Superior Vena Caval Obstruction (SVCO) - Management and Outcome

University Health Network, Toronto20 enrolled

Overview

All patients with symptomatic malignant SVCO deemed suitable for treatment either with radiation therapy or by stenting will be eligible. They will receive whichever treatment is deemed most clinically appropriate. Symptomatic response, time to onset of palliation, duration of symptom control and survival will be assessed.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Superior Vena Cava Syndrome

Interventions

Management and Outcome of SVCOBEHAVIORAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Symptomatic clinical and radiological diagnosis of superior vena caval obstruction. * Underlying histological diagnosis deemed appropriate for palliative radiotherapy as treatment by investigator. Patients with chemosensitive tumours such as small cell lung cancer (both untreated and recurrent), lymphoma and testicular tumours, will be eligible if radiation is deemed to be appropriate treatment.

Locations (1)

University Health Network

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Improvement in an index symptom at 4 weeks as recorded by a daily symptom diary

Secondary Outcomes

Time to onset of palliation

Duration of symptom control

Survival

Number of days spent in hospital

Requirement for further treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.